Tesamorelin and CJC-1295 are both GHRH analogues acting on the same receptor, which makes their comparison unusually clean: same mechanism class, radically different evidence tiers. Tesamorelin completed Phase 3 trials and holds FDA approval (as Egrifta) for a specific indication; CJC-1295 stopped at early-phase pharmacology studies. The choice between them is mostly a choice about what kind of evidence you want behind the compound.
| Attribute | Tesamorelin | CJC-1295 |
|---|---|---|
| Class | Stabilised GHRH analogue (trans-3-hexenoyl modification) | Long-acting GHRH analogue (DAC modification) |
| Evidence tier | Completed Phase 3 programme (NEJM 2007 + follow-ups) | Early-phase human pharmacology only (JCEM 2006) |
| Approval | FDA-approved (Egrifta, 2010) for HIV-associated lipodystrophy; not EU-authorised | Never approved anywhere |
| Demonstrated effect | Visceral fat reduction with lean mass preserved (in the trial population) | Elevated GH/IGF-1 levels for days per dose |
| Half-life | Short (minutes–hours); daily dosing in trials | Days (albumin-bound) |
| WADA status | Prohibited | Prohibited |
| In the Body Pharm catalogue | Yes | Yes, combined with ipamorelin |
Both compounds stimulate the GHRH receptor, raising growth hormone and IGF-1. Tesamorelin took that mechanism through the full clinical machinery: 26-week randomised Phase 3 trials in HIV-associated lipodystrophy showing significant visceral-fat reduction, an FDA review, and an approved label. CJC-1295’s human record is a handful of early pharmacology studies establishing its long half-life and hormone elevation: no outcome trials, no review, no label.
Tesamorelin’s evidence is real but narrow: it comes from HIV patients with abdominal fat accumulation, and its approval covers exactly that. Extrapolating the visceral-fat effect to other populations is a hypothesis, not a demonstrated result. The same caution that applies to CJC-1295’s hormone-level data applies to tesamorelin outside its trial population.
Tesamorelin’s short half-life meant daily dosing in its trials, mirroring the natural pulse; CJC-1295 produces a sustained multi-day elevation from a single exposure. They also differ in pairing conventions: CJC-1295 is almost always studied alongside ipamorelin, which is how we supply it, in one combined pen, while tesamorelin’s literature is standalone and we supply it on its own.
Tesamorelin, by a wide margin: completed Phase 3 trials and an FDA-approved indication against early-phase pharmacology studies. The caveat is that the evidence is specific to HIV-associated lipodystrophy.
No. Egrifta holds FDA approval in the US for one indication; there is no EMA marketing authorisation. Our tesamorelin pen sits outside the approved supply chain and is not Egrifta.
Both are GHRH-receptor analogues, so the core mechanism matches. They differ in molecular stabilisation, half-life (hours vs days), and the depth of evidence behind each.
Only tesamorelin has demonstrated body-composition outcomes in controlled human trials. CJC-1295 has shown hormone-level changes, not trial-verified composition results.
This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Where a compound has held a marketing authorisation, approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.
Both are GHRH analogues, and on mechanism they are close relatives. On evidence they are not comparable in the way a side-by-side table implies: one has completed randomised controlled trials in a defined patient population, the other has 28- and 49-day pharmacology studies in healthy volunteers.
Spotlight on tesamorelin in HIV-associated lipodystrophy. PMID 22050344; Clinical Review Report: Tesamorelin (Egrifta). PMID 30920787; Efficacy and safety of tesamorelin in people living with HIV with lipodystrophy: systematic review and meta-analysis. PMC13428105; Teichman SL et al. CJC-1295. J Clin Endocrinol Metab 2006. PMID 16352683
Nothing has compared them directly. The comparison is indirect and the two evidence bases answer different questions.
Tesamorelin: two 26-week randomised controlled trials in patients with HIV-associated central fat accumulation. Endpoint: visceral adipose tissue, which was reduced, without a clinically significant change in subcutaneous fat. The reduction was maintained through 52-week extensions and reversed on discontinuation. Treatment-emergent serious adverse events occurred in fewer than 4% over 26 weeks, mostly injection-site reactions or effects associated with growth-hormone therapy generally: joint pain, headache, peripheral oedema.
CJC-1295: two randomised, placebo-controlled ascending-dose trials of 28 and 49 days in healthy adults. Endpoint: hormone concentrations. GH raised two- to ten-fold for six days or more, IGF-1 by 1.5- to three-fold for nine to eleven days.
One measured a clinical outcome in patients. The other measured a biomarker in volunteers. Both are legitimate; they are not the same currency, and both appear under peptides for muscle on that understanding.
Tesamorelin is short-acting and its trials used daily dosing, mirroring the natural pulse. CJC-1295 with DAC produces sustained multi-day elevation from a single exposure, which is why its published schedules are weekly or biweekly.
That difference also shapes the pairing conventions: CJC-1295 is almost always studied alongside ipamorelin (see what CJC-1295 and ipamorelin are), while tesamorelin’s literature is standalone.
This is where most comparisons overreach. Tesamorelin’s approved indication is the reduction of excess abdominal fat in HIV-associated lipodystrophy, a specific metabolic condition with a specific fat-distribution problem (see what tesamorelin is).
Results in that population do not establish anything about a healthy adult, and no trial has tested that. A compound that reduces pathological visceral accumulation has not thereby been shown to do anything comparable in someone without the condition.
Tesamorelin was approved as Egrifta for that indication. CJC-1295 has never been approved anywhere. Neither of our pens, TESAMORELIN 32 or the combined CJC-1295 & IPAMORELIN, is an authorised product. Egrifta holds FDA approval in the United States; its EU application was withdrawn in 2012 before a decision, so it has never been authorised in the EU.
Related: growth hormone peptides, CJC-1295 vs Sermorelin.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy